You have been invited to take part in a research study designed to better understand the experiences of patients with autosomal dominant polycystic kidney disease, or ADPKD, who are taking tolvaptan (Jynarque®). Before you decide whether to take part, it is important for you to understand why the research is being done and what it will involve.
This study has 2 purposes: 1) To test a smartphone app created to help patients who are taking tolvaptan report their experiences with urination frequency and urgency. Every day for 1 week (7 days), you will complete a brief set of questions in the app and enter information each time you urinate, 2) To interview participants who used the urination-reporting app to learn more about their experiences with it.
The information collected through this study will be used to help make sure the app is easy to use and effective so that it can be included in future clinical trials.
If you choose to take part in this study, you will be asked to provide consent by clicking a series of boxes at the end of this form. If you do not provide consent, you cannot take part in this research study.
Further Information and Contact Details:
If you have questions, complaints, or concerns about the study, please contact the Principal Investigator of the study:
Meg O’Connor, MTS, MPH
QualityMetric Incorporated, LLC
1301 Atwood Ave, Suite 216E
Johnston, RI 02919, United States
Phone Number: +1-401-903-4667
Email: [email protected]